Spero Therapeutics (NASDAQ:SPRO) Downgraded by Evercore ISI to “In-Line”

Evercore ISI lowered shares of Spero Therapeutics (NASDAQ:SPRO) from an outperform rating to an in-line rating in a research note published on Friday morning, Marketbeat.com reports. They currently have $5.00 target price on the stock.

Several other research firms have also recently weighed in on SPRO. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Spero Therapeutics in a research report on Monday, December 2nd. Finally, TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th.

Spero Therapeutics Price Performance

Spero Therapeutics stock opened at $0.96 on Friday. The stock’s fifty day moving average price is $1.20 and its two-hundred day moving average price is $1.29. The firm has a market cap of $52.07 million, a PE ratio of 13.65 and a beta of 0.59. Spero Therapeutics has a one year low of $0.95 and a one year high of $1.89.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Spero Therapeutics stock. Acadian Asset Management LLC increased its stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 40.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,071,860 shares of the company’s stock after acquiring an additional 309,262 shares during the quarter. Acadian Asset Management LLC owned about 1.99% of Spero Therapeutics worth $1,392,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.